

# FOSFOMYCIN

|                         |   |
|-------------------------|---|
| BRAND NAME              | FOMICYT<br>Other brands may be available  |
| DRUG CLASS              | Antibiotic  |
| AVAILABILITY            | Vial contains 2 g, 4 g or 8 g of fosfomycin as disodium fosfomycin. <sup>1</sup><br>Fomicyt also contains succinic acid. <sup>1</sup><br>Each 1 g of fosfomycin contains 14 mmol of sodium. <sup>1</sup><br>Available through the Special Access Scheme.  |
| pH                      | No information  |
| PREPARATION             | <b>Fomicyt:</b> reconstitute the 2 g vial with 50 mL, the 4 g vial with 100 mL or the 8 g vial with 200 mL of glucose 5% or glucose 10%. <sup>1</sup><br><b>Other brands:</b> reconstitute the vial with 10-20 mL of water for injections or glucose 5% and then dilute further for infusion. <sup>2</sup><br>The solution is clear and colourless to pale yellow. <sup>1</sup><br>Powder volume: 2 g - 1 mL    4 g - 2 mL    8 g - 4 mL <sup>1</sup> |
| STABILITY               | Vial: store at 25 °C. <sup>1</sup><br>Reconstituted solution: stable for 24 hours at 25 °C protected from light. <sup>1</sup>   |
| ADMINISTRATION          |   |
| <b>IM injection</b>     | Not recommended   |
| <b>SUBCUT injection</b> | Not recommended   |
| <b>IV injection</b>     | Not recommended <sup>1</sup>  |
| <b>IV infusion</b>      | Infuse the 2 g dose over at least 15 minutes, the 4 g dose over at least 30 minutes and the 8 g dose over at least 1 hour. <sup>1</sup>   |
| COMPATIBILITY           |   |
| <b>Fluids</b>           | Glucose 5% <sup>1</sup> , glucose 10% <sup>1</sup>  |
| <b>Y-site</b>           | Some information is available <sup>2</sup>  |
| INCOMPATIBILITY         |   |
| <b>Fluids</b>           | Fat emulsion <sup>2</sup>   |
| <b>Drugs</b>            | Albumin <sup>2</sup> , amiodarone <sup>2</sup> , anidulafungin <sup>2</sup> , caspofungin <sup>2</sup> , ceftaroline fosamil <sup>2</sup> , ciprofloxacin <sup>2</sup> , daptomycin <sup>2</sup> , defibrotide <sup>3</sup> , isavuconazole <sup>2</sup> , labetalol <sup>2</sup> , midazolam <sup>2</sup> , mycophenolate mofetil <sup>2</sup> , nicardipine <sup>2</sup> , ondansetron <sup>2</sup> , propofol <sup>2</sup>                         |
| SPECIAL NOTES           | May cause phlebitis. <sup>1</sup><br>May cause hypokalaemia. Do not infuse faster than recommended rates. Monitor for signs including weakness, tiredness, oedema or muscle twitching. <sup>1</sup><br>A low-sodium diet may be required during treatment with fosfomycin. <sup>1</sup>   |

## REFERENCES

1. Fomicyt. Summary of product characteristics. Theale, UK: Nordic Pharma UK. Approved 19/06/2015. Updated 11/06/2017. Available from [www.medicines.org.uk](http://www.medicines.org.uk). Accessed 27/08/2019.
2. Fosfomycin sodium. In: IV index [internet]. Trissel's 2 clinical pharmaceuticals database (parenteral compatibility). Greenwood Village, CO: Truven Health Analytics. Accessed 28/04/2020.
3. Correard F, Savry A, Gauthier-Villano, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. *Am J Health-Syst Pharm* 2014; 71: 1288-91.